Literature DB >> 20110109

Expression of hepaCAM and its effect on proliferation of tumor cells in renal cell carcinoma.

Chunhua Xun1, Chunli Luo, Xiaohou Wu, Qiaolin Zhang, Ling Yan, Shali Shen.   

Abstract

OBJECTIVES: To evaluate hepaCAM (hepatocyte cell adhesion molecule) gene expression in patients with renal cell carcinoma (RCC) and to explore its effect on proliferation of 786-0 cells. hepaCAM is a tumor suppressor gene, which has been identified as a member of immunoglobulin superfamily cell adhesion molecule.
METHODS: Two-step reverse transcription-polymerase chain reaction was used to determine hepaCAM expression in 30 paired (RCC and the adjacent non-RCC) renal specimens. Transfection studies were carried out by expressing green fluorescent protein and green fluorescent protein-fused hepaCAM in 786-0 cells.
RESULTS: Significant downregulation of hepaCAM was detected in 25 of 30 RCC patients tested. When transfected into 786-0 cells, the number of colony formation was reduced by 5-fold according to colony formation assay. MTT (3-diphenyltetrazolium bromide) showed the inhibition rates on the fourth, fifth, and sixth days of culturing were 26.5%, 38.1%, and 35.7%, respectively.
CONCLUSION: Our data show that hepaCAM is frequently downregulated in RCC, and that exogenous hepaCAM exhibits antiproliferative effect on 786-0 cells, suggesting that silencing of hepaCAM may be associated with carcinogenesis of RCC. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110109     DOI: 10.1016/j.urology.2009.11.024

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.

Authors:  Shuzhe Yang; Xiaohou Wu; Chunli Luo; Cuicui Pan; Jun Pu
Journal:  World J Urol       Date:  2010-07-01       Impact factor: 4.226

2.  The SMAD2/3 pathway is involved in hepaCAM-induced apoptosis by inhibiting the nuclear translocation of SMAD2/3 in bladder cancer cells.

Authors:  Xiaorong Wang; E Chen; Min Tang; Xue Yang; Yin Wang; Zhan Quan; Xiaohou Wu; Chunli Luo
Journal:  Tumour Biol       Date:  2016-02-12

3.  HepaCAM inhibits clear cell renal carcinoma 786-0 cell proliferation via blocking PKCε translocation from cytoplasm to plasma membrane.

Authors:  Bing Tan; Jinxiang Tan; Hongfei Du; Zhen Quan; Xiangdong Xu; Xiaoliang Jiang; Chunli Luo; Xiaohou Wu
Journal:  Mol Cell Biochem       Date:  2014-02-11       Impact factor: 3.396

4.  HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.

Authors:  Zhongbo Du; Luo Li; Wei Sun; Xiao Wang; Yao Zhang; Zhixiong Chen; Mengjuan Yuan; Zhen Quan; Nanjing Liu; Yanni Hao; Ting Li; Jinhua Wang; Chunli Luo; Xiaohou Wu
Journal:  Int J Oncol       Date:  2018-04-12       Impact factor: 5.650

5.  HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain.

Authors:  Qingfu Deng; Li Luo; Zhen Quan; Nanjing Liu; Zhongbo Du; Wei Sun; Chunli Luo; Xiaohou Wu
Journal:  Mol Med Rep       Date:  2019-01-10       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.